CD47 and lymphoma: On the other hand, in patients with lymphoma, a recent phase 1b study showed that CD47 mAb in concert with rituximab showed enhanced effects by enhancing macrophage‐mediated antibody‐dependent cellular phagocytosis (Advani et al., 2018).